Skin compositions and methods of use thereof
View Patent ↗Provided are body corrective cosmetic formulations and methods of use thereof.
1. A body corrective film prepared by a process comprising the steps of:
a) applying a reactive reinforcing component to skin, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C1-20 alkyl, C2-20 alkenyl, C5-10 aryl, hydroxyl or C1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are each independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) applying a cross-linking component to said reactive reinforcing component,
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a body corrective film is formed on skin.
2. A method for correcting skin imperfections on a subject's skin comprising applying to said subject's skin a formulation comprising:
a) a reactive reinforcing component, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 200 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a cross-linking component;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a film is formed on skin, thereby correcting skin imperfections.
3. A method for delivering one or more agents to a subject, comprising applying to the subject's skin a formulation comprising:
a) a first reactive reinforcing component optionally comprising one or more said agents, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 200 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a second cross-linking component optionally comprising one or more said agents;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component such that a film is formed on skin, thereby delivering the agent to the subject.
4. A wrinkle corrective formulation for application to the skin, comprising:
a) a reactive reinforcing component, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a cross-linking component;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a wrinkle corrective film is formed on skin, and wherein said film when formed reduces the appearance of wrinkles.
5. A bag reducing formulation for application to the skin, comprising:
a) a reactive reinforcing component, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a cross-linking component;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a bag reducing film is formed on skin, and wherein said film when formed reduces the appearance of bags under the eyes.
6. A firmness imparting formulation for application to the skin, comprising:
a) a reactive reinforcing component, wherein the reactive reinforcing component comprises a (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a cross-linking component;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a firmness imparting film is formed on skin, and wherein said film when formed imparts an appearance of firmness to the skin.
7. A body corrective formulation for application to skin, comprising:
a) a reactive reinforcing component comprising (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;
wherein said organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:
wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;
p and q are each independently an integer from between 10 and 6000;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy;
R 4b , R 5b , R 9b and R 10b are in each occurrence independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;
m and n are each independently an integer from between 10 and 6000;
wherein said organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;
wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C.;
wherein said low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.;
wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.; and
b) a cross-linking component;
wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a body corrective film is formed on the skin.
8. The formulation of claim 7 , wherein said high viscosity organopolysiloxane comprises vinyl terminated organopolysiloxane.
9. The formulation of claim 7 , wherein said high viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane.
10. The formulation of claim 7 , wherein said low viscosity organopolysiloxane has a viscosity of about 500 to about 50,000 cSt or cP at 25° C.
11. The formulation of claim 7 , wherein said low viscosity organopolysiloxane comprises vinyl terminated organopolysiloxane.
12. The formulation of claim 7 , wherein said low viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane.
13. The formulation of claim 7 , wherein said hydride functionalized polysiloxane is alkyl terminated.
14. The formulation of claim 7 , wherein said hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers.
15. The formulation of claim 7 , wherein said hydride functionalized polysiloxane has at least 2 Si—H units on average.
16. The formulation of claim 7 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:10 to about 1:100.
17. The formulation of claim 7 , wherein said reinforcing constituent is selected from the group consisting of optionally surface treated mica, zinc oxide, titanium dioxide, aluminum oxide, clay or silica.
18. The formulation of claim 17 , wherein said reinforcing constituent is silica.
19. The formulation of claim 18 , wherein said silica is fumed silica.
20. The formulation of claim 19 , wherein said fumed silica is surface treated with hexamethyldisilazane.
21. The formulation of claim 7 , wherein the crosslinking component comprises a metal catalyst.
22. The formulation of claim 21 , wherein said catalyst is a platinum catalyst.
23. The formulation of claim 21 , wherein the catalyst comprises about 0.005 to about 0.05% of the cross-linking component.
24. The formulation of claim 7 , wherein the formulation, when crosslinked, produces a film having a leather adhesive force of greater than about 20 N/mm; a Young's Modulus of about 0.01 to about 1 MPa; a fracture strain of at least about 150%; a hysteresis of less than about 5%; or a combination thereof.
25. The formulation of claim 7 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:15 to about 1:40.
26. The formulation of claim 7 , wherein R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl.
27. The method of claim 2 , wherein correcting skin imperfections on a subject's skin is selected from reducing or masking the appearance of wrinkles or under eye bags on a subject's skin.
28. The formulation of claim 3 , wherein
R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C 1-20 alkyl;
R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are C 1-20 alkyl;
R 4b , R 5b , R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, or C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen.
29. The formulation of claim 3 , wherein said high viscosity organopolysiloxane comprises vinyl terminated organopolysiloxane.
30. The formulation of claim 3 , wherein said high viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane.
31. The formulation of claim 3 , wherein said low viscosity organopolysiloxane has a viscosity of about 500 to about 50,000 cSt or cP at 25° C.
32. The formulation of claim 3 , wherein said low viscosity organopolysiloxane comprises vinyl terminated organopolysiloxane.
33. The formulation of claim 3 , wherein said low viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane.
34. The formulation of claim 3 , wherein said hydride functionalized polysiloxane is alkyl terminated.
35. The formulation of claim 3 , wherein said hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers.
36. The formulation of claim 3 , wherein said hydride functionalized polysiloxane has at least 2 Si—H units on average.
37. The formulation of claim 3 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:10 to about 1:100.
38. The formulation of claim 3 , wherein said reinforcing constituent is selected from the group consisting of optionally surface treated mica, zinc oxide, titanium dioxide, aluminum oxide, clay or silica.
39. The formulation of claim 3 , wherein said reinforcing constituent is silica.
40. The formulation of claim 3 , wherein the crosslinking component comprises a metal catalyst.
41. The formulation of claim 40 , wherein said catalyst is a platinum catalyst.
42. The formulation of claim 41 , wherein the catalyst comprises about 0.005 to about 0.05% of the cross-linking component.
43. The formulation of claim 3 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:15 to about 1:40.
44. The formulation of claim 3 , wherein R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl.